Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 6/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247601 | 0.98 | SLC15A2 (0.42) | SLC15A2GHSRMMP1ERAP2ERAP1 | |
| SCHEMBL4587382 | 0.92 | SLC15A2 (0.41) | SLC15A2GHSRMMP1ERAP2ERAP1 | |
| SCHEMBL4588264 | 0.92 | SLC15A2 (0.41) | SLC15A2GHSRMMP1ERAP2ERAP1 | |
| SCHEMBL4587314 | 0.90 | SLC15A2 (0.39) | SLC15A2GHSRERAP2ERAP1LNPEP | |
| SCHEMBL2242457 | 0.90 | SLC15A2 (0.41) | SLC15A2GHSRMMP1ERAP2ERAP1 | |
| SCHEMBL5969804 | 0.90 | SLC15A2 (0.41) | SLC15A2GHSRMMP1ERAP2ERAP1 | |
| SCHEMBL1959812 | 0.90 | SLC15A2 (0.50) | SLC15A2GHSRERAP2ERAP1LNPEP | |
| SCHEMBL5969770 | 0.90 | SLC15A2 (0.50) | SLC15A2GHSRERAP2ERAP1LNPEP | |
| SCHEMBL1959809 | 0.90 | SLC15A2 (0.50) | SLC15A2GHSRERAP2ERAP1LNPEP | |
| SCHEMBL4589867 | 0.89 | PLG (0.40) | SLC15A2GHSRMMP1ERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384916-B2 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2008-06-10 | — | — | US | claimed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | claimed |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | claimed |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7384916-B2 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1866036-A2 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1765280-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN | PROCYTE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006101855-A2 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006004787-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN | PROCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| EP-0514460-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| US-5118665-A | Enhance or restore resistance of mammals to damage caused by release of reactive oxygen species | PROCYTE CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| WO-1991012267-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | RBP1, RBP4, SOD1 | SLC15A2 2656/4885GHSR 1411/4885MMP1 625/4885 |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | RBP1, RBP4, MC1R | SLC15A2 1582/4885GHSR 748/4885MMP1 1224/4885 |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | RBP1, RBP4, SOD1 | SLC15A2 2656/4885GHSR 1411/4885MMP1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.